Yazar "Ozgul, Mustafa" seçeneğine göre listele

Listeleniyor 1 - 8 / 8
  • Küçük Resim Yok
    Öğe
    Cardiac autonomic control during platelet apheresis
    (2022) Cakan, Pinar; Ozgul, Mustafa; Erkut, Mehmet Ali; Kaya, Emin; Yıldız, Sedat; Kuku, İrfan
    Aim: The aim of the current study was to assess the effects of platelet apheresis (PA) on cardiac autonomic control by the means of short-term heart-rate variability (HRV) technique. Materials and Methods: A total of 100 platelet donors (age: 29.0±0.9 years, body mass index: 25.8±0.7) were evaluated for heart rate (HR), HRV and blood pressure through a full cycle of PA. HR and HRV were assessed by 5-min continuous electrocardiographic recordings at four occasions, i.e., 5 min before (-5 min), and at 10th min (10 min), 45th min (45 min) and at post 5th min of PA. Time- and frequency-domain parameters of HRV were calculated using specific software. Low-frequency (LF)/high-frequency (HF) ratio was also determined. Blood pressure (BP) was also recorded 5 min before and 5 min after PA. Results: HR increased towards 45th min and declined towards the end of the PA (P < 0.05). Both time- and frequency-domain parameters decreased towards the 45th min and increased towards the last 5th mins (P < 0.05). LF/HF was increased towards 45th min and declined towards the end of the PA. Systolic BP decreased from 111 (106-120) mm Hg to 107 (99-115) mm Hg (P=0.003). Conclusions: HR, HRV and blood pressure were dynamically changed throughout the process of PA. These changes appeared to be caused by increased cardiac sympathovagal balance, resembling the pattern observed during whole blood donation.
  • Küçük Resim
    Öğe
    The effects of sedation with propofol and propofol- ketamin combination on postoperative cognitive function in elderly patients undergoing spinal anesthesia
    (2021) Colak, Yusuf Ziya; Ozgul, Mustafa; Demiroz Aslan, Duygu; Cumurcu, Hatice; Colak, Cemil; Durmus, Mahmut
    Aim: Elderly patients frequently require surgery. Postoperative cognitive dysfunction (POCD) is an adverse event and reduces the patient’s quality of life. We aimed to compare the effects of sedation applied with propofol or propofol-ketamine (ketofol) combination on hemodynamics and POCD during spinal anesthesia in elderly patients undergoing urological surgery. Materials and Methods: Study was performed on 60 ASA I-III patients over 65 years of age. Before the operation (standardized Mini Mental Test) sMMT was applied by a blind researcher. The cases were randomly divided into two groups as propofol (Group P, n=30) and ketofol (Group K, n=30). ECG, SpO 2 , Bispectral Index (BIS), noninvasive blood pressure (NIBP) was monitored. After spinal anesthesia, group P received propofol 0.5 mg/kg IV bolus and then 1.5 mg/kg/hour infusion. Group K received propofol 0.4 mg/ kg and ketamine 0.1 mg/kg IV bolus and then propofol 1.2 mg/kg/hour and ketamine 0.3 mg/kg/hour infusion. Hemodynamic and respiratory data were recorded. The sedation level was monitored by RAMSAY sedation score. sMMT was repeated by the researcher who performed the initial test at postoperative first 24 hours and postoperative 3rd day. Results: Significant decreases were observed for heart rate, SAP, and MAP in both groups compared with baseline values. No statistically significant difference was detected between the groups in sMMT values at postoperative 1 st and 3 rd days. Within- group comparisons revealed significant differences between preoperative sMMT and postoperative 1 st day sMMT and between postoperative 1 st and postoperative 3 rd day sMMT (p< 0.001). No difference was detected between preoperative and postoperative 3 rd day sMMT (p< 0.25). In Group P, there was statistically significantly higher injection pain (p<0.05). Conclusion: In this study we found that the recovery period of the patients was longer and BIS values were higher in group K, but no significant difference could be found in hemodynamic and cognitive functions.
  • Küçük Resim
    Öğe
    Life saving effect of early use of convalescent plasma in Covid-19 treatment
    (2021) Sarici, Ahmet; Erkurt, Mehmet Ali; Kuku, Irfan; Bicim, Soykan; Berber, Ilhami; Kaya, Emin; Ozgul, Mustafa
    Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, which is detected by the transmission from bat to person in Wuhan Province of China, has shown its effect all over the world in a very short time. There is no treatment method proven effective in Coronavirus disease 2019 (COVID-19) pandemics. The whole world is still working on it. Convalescent Plasma (CP) treatment is a passive antibody treatment that has been shown to be effective during periods of epidemic disease in history. CP treatment is interesting in the treatment of virus infection without vaccine or specific treatment, such as SARS-CoV-2, which causes COVID-19. The mechanisms of action of CP include neutralizing the virus by direct binding, initiating virus elimination by complement activation, antibody-dependent cellular cytotoxicity and / or phagocytosis. Neutralizing antibodies are the most important mechanisms of action. The most important point in recovery is the inactivation of the virus and the prevention of viral replication. It was demonstrated for the first time that CP significantly reduced mortality in COVID-19 disease. Our results of CP treatment in COVID-19 patients have been published. We have shown that CP is effective and safe in COVID-19 disease. We aimed to gather CP experiences up to date in COVID-19.
  • Küçük Resim Yok
    Öğe
    Life saving effect of early use of convalescent plasma inCovid-19 treatment
    (2021) Sarıcı, Ahmet; Erkurt, Mehmet Ali; Kuku, İrfan; Biçim, Soykan; Berber, İlhami; Kaya, Emin; Ozgul, Mustafa
    Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, which is detected by the transmission from bat to person in Wuhan Province of China, has shown its effect all over the world in a very short time. There is no treatment method proven effective in Coronavirus disease 2019 (COVID-19) pandemics. The whole world is still working on it. Convalescent Plasma (CP) treatment is a passive antibody treatment that has been shown to be effective during periods of epidemic disease in history. CP treatment is interesting in the treatment of virus infection without vaccine or specific treatment, such as SARSCoV-2, which causes COVID-19. The mechanisms of action of CP include neutralizing the virus by direct binding, initiating virus elimination by complement activation, antibody-dependent cellular cytotoxicity and / or phagocytosis. Neutralizing antibodies are the most important mechanisms of action. The most important point in recovery is the inactivation of the virus and the prevention of viral replication. It was demonstrated for the first time that CP significantly reduced mortality in COVID-19 disease. Our results of CP treatment in COVID-19 patients have been published. We have shown that CP is effective and safe in COVID-19 disease. We aimed to gather CP experiences up to date in COVID-19.
  • Küçük Resim Yok
    Öğe
    Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia
    (Pergamon-Elsevier Science Ltd, 2020) Erkurt, Mehmet Ali; Sarici, Ahmet; Berber, Ilhami; Kuku, Irfan; Kaya, Emin; Ozgul, Mustafa
    Aim: Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19. Methods: CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days after complete recovery from patients who had mild or moderate infection with Sars-Cov-2 infection. The collected CP (200cc) were applied to severe Covid-19 patients. Laboratory values of patients just before CP and after 7 days were compared. Results: There were no statistically significant differences in leukocyte, neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO(2) and total bilirubin values just before and after 1 week of CP. A statistically significant difference was found between age and lymphocyte values of living and dying patients. The patients who died were determined to have older age (74,6 vs 61,85, p-0,018) and more severe lymphopenia (0,47 vs 1,18, p = 0,001). Conclusion: CP therapy has the potential to provide immediate and promising treatment options before specific vaccines and treatments are developed. In early stage Covid-19 patients who do not need mechanical ventilation, CP treatment may be a curative treatment option.
  • Küçük Resim
    Öğe
    Successful treatment with convalescent plasma in Covid-19 disease in relaps/refractory multiple myeloma
    (2021) Sarici, Ahmet; Bicim, Soykan; Erkurt, Mehmet Ali; Berber, Ilhami; Kaya, Emin; Kuku, Irfan; Ozgul, Mustafa
    The Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus detected in the Wuhan Province of the People's Republic of China caused a pandemic in a very short time all over the world. Convalescent plasma (CP) therapy is a passive antibody therapy that has been shown to be effective in epidemic periods. CP therapy has been of interest in the treatment of infection with no vaccine or specific treatment, such as the Sars-CoV-2 infection that causes COVID-19. We aimed to report our CP experience in Sars-Cov-2 infection in our relapsed / refractory Multiple myeloma (MM) patient.
  • Küçük Resim Yok
    Öğe
    Successful treatment with convalescent plasma inCovid-19 disease in relaps/refractory multiple myeloma
    (2021) Sarıcı, Ahmet; Biçim, Soykan; Erkurt, Mehmet Ali; Berber, İlhami; Kaya, Emin; Kuku, İrfan; Ozgul, Mustafa
    The Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus detected in the Wuhan Province of the People's Republic of China caused a pandemic in a very short time all over the world. Convalescent plasma (CP) therapy is a passive antibody therapy that has been shown to be effective in epidemic periods. CP therapy has been of interest in the treatment of infection with no vaccine or specific treatment, such as the Sars-CoV-2 infection that causes COVID-19. We aimed to report our CP experience in Sars-Cov-2 infection in our relapsed / refractory Multiple myeloma (MM) patient.
  • Küçük Resim Yok
    Öğe
    Therapeutic plasma-exchange in hematologic disease: Results from a single center in Eastern Anatolia
    (Pergamon-Elsevier Science Ltd, 2013) Erkurt, Mehmet Ali; Kuku, Lrfan; Kaya, Emin; Ozgen, Unsal; Berber, Ilhami; Koroglu, Mustafa; Ozgul, Mustafa
    Therapeutic plasma-exchange (TPE) is used as primary and adjunctive therapy in treatment of several hematologic diseases. We retrospectively evaluated the results of TPE in hematologic diseases during 2008-2012. A total of 301 TPE procedures were performed in 44 patients (19 male and 25 female, with mean age of 50.6 +/- 15 years). Fifteen of 44 patients had thrombotic thrombocytopenic purpura (TTP), 14 patients had HELLP syndrome (Hemolysis Elevated Liver enzymes, Low Platelet count), 10 patients had multiple myeloma-hyperviscosity and the rest five patients had snake bite. Fresh frozen plasma (FFP) was used as replacement fluid. Complete response (CR) was achieved on 13 patients (87%) in primarily TTP. CR was achieved in all other three diseases. Total complications were detected in 8.1% of the TPE procedures. Adverse events (AEs), were seen in 5.4% of all procedures. None of the patients died from any complication. AE occurred in 4% (Grade-I), 1% (Grade-II), and 0.3% (Grade-III) of the procedures. The most common AE were nausea/vomiting, hypotension, pruritus and abdominal pain. TPE is effectively and safely carried out in our center in hematologic diseases. (C) 2013 Elsevier Ltd. All rights reserved.